BD Gains FDA Clearance for Surgiphor 1000mL Surgical Irrigation System

Becton, Dickinson and Company BDX, popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system. The product is the first antimicrobial irrigation solution available in a 1000mL format designed for powered lavage, providing a standardized and OR-ready option to support surgical safety and procedural performance. The Surgiphor 1000mL expands BD’s existing Surgiphor portfolio and enables clinicians to mechanically remove debris and microorganisms from wounds during powered irrigation procedures.

Per management, the FDA clearance further strengthens the company’s leadership in surgical irrigation technologies. The Surgiphor 1000mL antimicrobial irrigation system is designed to deliver consistent and safe irrigation performance, supporting surgical teams in improving procedural efficiency and patient care outcomes.

Likely Trend of BDX Stock Following the News

Shares of BDX have lost 1.6% since the announcement on Monday. Over the past six months, shares of the company declined 10.9% against the industry’s 23.3% growth and the S&P 500’s 6.4% rise.

In the long run, the FDA 510(k) clearance for BD’s Surgiphor 1000mL is expected to strengthen the company’s position in the wound irrigation systems market. By expanding the Surgiphor platform with a larger-volume powered irrigation option, the company can strengthen adoption across hospitals that rely on standardized, ready-to-use solutions to improve surgical outcomes and operational efficiency. The innovation also supports BDX’s broader strategy of expanding its surgery portfolio with integrated solutions that combine devices, consumables and clinical workflow support, which could help drive recurring product demand and strengthen hospital partnerships.

BDX currently has a market capitalization of $49.60 billion.

Image Source: Zacks Investment Research

More on the Surgiphor 1000mL

The Surgiphor 1000mL antimicrobial irrigation system is supplied as a ready-to-use sterile solution, eliminating the need for manual mixing by hospital staff. This design helps reduce preparation time in the operating room while supporting adherence to established safety standards for surgical wound irrigation. Building on the market adoption of the original Surgiphor antimicrobial irrigation system, the 1000mL configuration provides operating room teams with a higher-volume option designed to integrate with existing powered irrigation systems.

Engineered to work with widely used powered lavage devices, the system features a powered-device adapter along with a Y-connector that allows clinicians to switch between saline and Surgiphor solution during procedures. A twist cap is also included to support manual application when needed, providing additional flexibility for different clinical scenarios.

The design incorporates integrated venting to facilitate consistent and uninterrupted fluid flow, while the collapsible bottle structure helps ensure efficient evacuation and easier handling during use. The solution contains terminally sterile PVP-I (povidone-iodine) and forms part of BD’s broader surgical irrigation portfolio, offering terminally sterile PVP-I solutions in multiple volumes and delivery formats.

With the introduction of the 1000mL configuration, the Surgiphor antimicrobial irrigation system portfolio now includes both manual and powered irrigation options, allowing clinicians to choose formats that best align with procedural requirements and operating room workflows.

Industry Prospects Favoring the Market

Going by the data provided by Precedence Research, the wound irrigation systems market is valued at $356.16 million in 2026 and is expected to witness a CAGR of 4.7% through 2035.

Factors like the increasing chronic wound cases and the adoption of advanced, automated devices that improve infection control and healing efficacy are boosting the market’s growth.

Other News

BD recently introduced the BD Vacutainer Urine Complete Cup Kit, a three-tube urine collection system aimed at expanding diagnostic testing from a single specimen. The launch highlights the company’s efforts to improve preanalytical workflows and laboratory efficiency. The kit is designed to preserve specimen integrity, reduce healthcare worker exposure and minimize repeat collections. Its unique third-tube configuration allows additional testing from one sample while eliminating manual transfers, thereby lowering contamination risks and improving operational safety in clinical environments.

In January, BD announced the commercial launch of BD Research Cloud 7.0, advancing its AI strategy in flow cytometry and life sciences research. The release features BD Horizon Panel Maker, an AI-driven tool that automates panel design — an essential step in immunology and oncology experiments to improve data quality and reliability. The cloud-based platform supports collaboration, workflow optimization and laboratory management.

BDX’s Zacks Rank & Key Picks

Currently, BDX carries a Zacks Rank #4 (Sell).

Some top-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Phibro Animal Health PAHC and Cardinal Health CAH.

Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.

ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 14% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.

Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.

Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.